EUVIMEDEUVIMED entdecken
Open Access

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab

Colleen A Ramsower iD, Allison Rosenthal, Ryan S Robetorye, Raphael Mwangi, Matthew Maurer iD, Diego Villa iD, Tim McDonnell, Andrew Feldman, Jonathon B Cohen iD, Thomas Habermann, Elias Campo, Guillem Clot und 13 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Colleen A Ramsower und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Mayo Clinic, Scottsdale, Arizona, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high‐risk call by a simplified MCL international prognostic index (s‐MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high‐risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s‐MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk‐stratify older MCL patients in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAdultHumansAgedRituximabBendamustine HydrochlorideBiomarkersPrognosisAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

MCL35MIPImantle cell lymphomaprognosisproliferation

Substanzen

RituximabBendamustine HydrochlorideBiomarkers

Autor:innen und Institutionen

  • Department of Research, Mayo Clinic, Scottsdale, Arizona, USA.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Arizona, Phoenix, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Colleen A Ramsower, Matthew Maurer, Diego Villa, Jonathon B Cohen, Jose Ignacio Martin-Subero, James R Cook, Brian Hill, Philipp W Raess, Sylvia Hartmann, Harald Holte, Lisa Rimsza

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Ramsower, C. A., Rosenthal, A., Robetorye, R. S., Mwangi, R., Maurer, M., Villa, D., McDonnell, T., Feldman, A., Cohen, J. B., Habermann, T., Campo, E., Clot, G., Bühler, M. M., Kulis, M., Martin-Subero, J. I., Giné, E., Cook, J. R., Hill, B., Raess, P. W., …, & Rimsza, L. (2024). Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab. British Journal of Haematology. https://doi.org/10.1111/bjh.19153

Vancouver

Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, et al. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab. British Journal of Haematology. 2024. doi:10.1111/bjh.19153

BibTeX
@article{Ramsower2024,
  author = {Ramsower, Colleen A and Rosenthal, Allison and Robetorye, Ryan S and Mwangi, Raphael and Maurer, Matthew and Villa, Diego and McDonnell, Tim and Feldman, Andrew and Cohen, Jonathon B and Habermann, Thomas and Campo, Elias and Clot, Guillem and Bühler, Marco M and Kulis, Marta and Martin-Subero, Jose Ignacio and Giné, Eva and Cook, James R and Hill, Brian and Raess, Philipp W and Beiske, Klaus H and Reichart, Alexander and Hartmann, Sylvia and Holte, Harald and Scott, David and Rimsza, Lisa},
  title = {Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19153}
}
Kostenlos starten →